These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 37805442

  • 1. [Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung adenocarcinoma PC9/GR cells and its mechanism].
    Jia YL, Zhao Y, Zhen SM, Cheng ZS, Zheng BY, Liu YP, Liu LH.
    Zhonghua Zhong Liu Za Zhi; 2023 Sep 23; 45(9):779-786. PubMed ID: 37805442
    [Abstract] [Full Text] [Related]

  • 2. [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
    Wang Q, Li M, Hu C.
    Zhongguo Fei Ai Za Zhi; 2015 Apr 23; 18(4):193-8. PubMed ID: 25936882
    [Abstract] [Full Text] [Related]

  • 3. 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
    Yang B, Yang ZG, Gao B, Shao GG, Li GH.
    Int J Clin Exp Pathol; 2015 Apr 23; 8(10):12961-6. PubMed ID: 26722491
    [Abstract] [Full Text] [Related]

  • 4. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C, Gao W, Liu J, Cheng H, Hao J.
    Respir Res; 2020 Aug 10; 21(1):210. PubMed ID: 32778129
    [Abstract] [Full Text] [Related]

  • 5. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation.
    Ma C, Zhang X, Mo X, Yu Y, Xiao Z, Wu J, Ding L, Lei C, Zhu Y, Zhang H.
    Phytomedicine; 2024 Mar 10; 125():155351. PubMed ID: 38232540
    [Abstract] [Full Text] [Related]

  • 6. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH, Jung SS, Yeo MK, Lee DH, Yoo G, Cho SY, Oh IJ, Kim JO, Park HS, Chung C, Lee JE.
    BMC Cancer; 2020 Jun 18; 20(1):571. PubMed ID: 32552717
    [Abstract] [Full Text] [Related]

  • 7. Macrophage renewal modes affect acquired resistance to gefitinib in EGFR‑mutant lung cancer PC‑9 cells.
    Zhao B, Zhang Y, Lu S, Li M.
    Oncol Rep; 2023 Feb 18; 49(2):. PubMed ID: 36562379
    [Abstract] [Full Text] [Related]

  • 8. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY, Kim YG, Nam SJ, Keam B, Kim TM, Jeon YK, Kim CW.
    Mol Cancer Ther; 2016 Jun 18; 15(6):1387-96. PubMed ID: 26883272
    [Abstract] [Full Text] [Related]

  • 9. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC.
    Chen Y, Zhang C, Jin S, Li J, Dai J, Zhang Z, Guo R.
    J Cell Mol Med; 2023 Jul 18; 27(14):2032-2044. PubMed ID: 37278440
    [Abstract] [Full Text] [Related]

  • 10. [FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer].
    Peng C, Li P, Yang M, Chen D, Huang Y.
    Zhongguo Fei Ai Za Zhi; 2021 Aug 20; 24(8):538-547. PubMed ID: 34334155
    [Abstract] [Full Text] [Related]

  • 11. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
    Huang L, Hou M, Liu J, Li Y, Shen W, Zhou Q.
    Zhongguo Fei Ai Za Zhi; 2022 Nov 20; 25(11):771-781. PubMed ID: 36419390
    [Abstract] [Full Text] [Related]

  • 12. Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
    Lai XY, Shi YM, Zhou MM.
    Kaohsiung J Med Sci; 2023 Jul 20; 39(7):699-709. PubMed ID: 37057810
    [Abstract] [Full Text] [Related]

  • 13. [Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].
    Qin X, Liu B, Li Y, You J, Zhou Q.
    Zhongguo Fei Ai Za Zhi; 2011 Jun 20; 14(6):478-83. PubMed ID: 21645449
    [Abstract] [Full Text] [Related]

  • 14. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
    Li Q, Wang Y, He J.
    J Clin Lab Anal; 2021 Jul 20; 35(7):e23853. PubMed ID: 34057242
    [Abstract] [Full Text] [Related]

  • 15. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ, Hung JY, Tsai MJ, Wu KL, Liu TC, Chou SH, Lee JY, Hsu JS, Huang MS, Chong IW.
    BMC Pharmacol Toxicol; 2017 May 10; 18(1):21. PubMed ID: 28486985
    [Abstract] [Full Text] [Related]

  • 16. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J, Zhang L, Zhu H, Pan W, Zhang N, Li Y, Yang M.
    DNA Cell Biol; 2018 Nov 10; 37(11):903-908. PubMed ID: 30277797
    [Abstract] [Full Text] [Related]

  • 17. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
    Lee Y, Choi YR, Kim KY, Shin DH.
    Oncotarget; 2016 Jul 12; 7(28):43315-43323. PubMed ID: 27270313
    [Abstract] [Full Text] [Related]

  • 18. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J, Kwak KJ, Wu Z, Yang D, Li J, Chang M, Song Y, Zeng H, Lee LJ, Hu J, Bai C.
    Cell Physiol Biochem; 2018 Jul 12; 47(5):1909-1924. PubMed ID: 29961070
    [Abstract] [Full Text] [Related]

  • 19. Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells.
    Lee YJ, Kim SY, Lee C.
    Mol Med Rep; 2019 Apr 12; 19(4):3230-3236. PubMed ID: 30816529
    [Abstract] [Full Text] [Related]

  • 20. Synergistic anti-tumor effects of lenalidomide and gefitinib by upregulating ADRB2 and inactivating the mTOR/PI3K/AKT signaling pathway in lung adenocarcinoma.
    Zhou S, Deng M, Bian X, Shi J, Liang R, Tao M.
    Cell Mol Biol (Noisy-le-grand); 2024 Feb 29; 70(2):120-127. PubMed ID: 38430032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.